Back to search

Peptide record

TPDB06359

Antibacterial Toxicity standard
11 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB06359
Antibacterial Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia
standard
No
A 11-aa standard natural multi-activity (Antibacterial and Toxicity) peptide sequence curated from AntiBP3 and Peptipedia, with an available 3D structural model.
Sequence
KKFPWWWPFKK
Physicochemical Analysis
C85H112N18O12
ARNDCEQGHILMSTYV
K
1577.94
11.00
4
0
5
+4
-2.95
-1.445
0.00
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
16500
1045.67
0
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
0
L
4
K
0
M
2
F
2
P
0
S
0
T
3
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 0 K: 4 M: 0 F: 2 P: 2 S: 0 T: 0 W: 3 Y: 0 V: 0
Chemical Descriptors
11
C85H112N18O12
1577.94
11.00
+4
-2.95
-1.445
Evidence Records 7 records
Evidence 1 Activity

Activity

MIC
Antibacterial
4 µg/mL

Target

Escherichia coli KCTC 1682

Source & Reference

NA

Other

Active against E. coli KCTC 1682 (MIC 4 ug/ml), S. typhimurium KCTC 1926 (MIC 4 ug/ml), B. subtilis KCTC 3068 (MIC 2 ug/ml), and S. aure
Evidence 2 Activity

Activity

MIC
Antibacterial
4 µg/mL

Target

S. typhimurium KCTC 1926

Source & Reference

NA

Other

Active against E. coli KCTC 1682 (MIC 4 ug/ml), S. typhimurium KCTC 1926 (MIC 4 ug/ml), B. subtilis KCTC 3068 (MIC 2 ug/ml), and S. aureus KCTC 1621 or 2 strains MRSA (MIC 2-8
Evidence 3 Activity

Activity

MIC
Antibacterial
2 µg/mL

Target

B. subtilis KCTC 3068

Source & Reference

NA

Other

Active against E. coli KCTC 1682 (MIC 4 ug/ml), S. typhimurium KCTC 1926 (MIC 4 ug/ml), B. subtilis KCTC 3068 (MIC 2 ug/ml), and S. aureus KCTC 1621 or 2 strains MRSA (MIC 2-8 ug/ml), 2 strains vancomycin-resistan
Evidence 4 Activity

Activity

MIC
Antibacterial
2-8 µg/mL

Target

Staphylococcus aureus KCTC 1621 or MRSA

Source & Reference

NA

Other

ug/ml), S. typhimurium KCTC 1926 (MIC 4 ug/ml), B. subtilis KCTC 3068 (MIC 2 ug/ml), and S. aureus KCTC 1621 or 2 strains MRSA (MIC 2-8 ug/ml), 2 strains vancomycin-resistant E. faecium (MIC 8 ug/ml) anti-VRE. Nonstandard assays in
Evidence 5 Activity

Activity

MIC
Antibacterial
8 µg/mL

Target

E. faecium

Source & Reference

NA

Other

and S. aureus KCTC 1621 or 2 strains MRSA (MIC 2-8 ug/ml), 2 strains vancomycin-resistant E. faecium (MIC 8 ug/ml) anti-VRE. Nonstandard assays in 50% LB.
Evidence 6 Activity

Activity

Toxicity
Hemolytic Cytotoxic
- | NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Selective cytotoxicity following Arg-to-Lys substitution in tritrpticin adopting a unique amphipathic turn structure. | FEBS Lett | 2003
Evidence 7 Activity

Activity

50% Hemolysis
Toxicity
>200 µM
Hemolytic Cytotoxic
50% Hemolysis | >200 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of perfectly symmetric Trp-rich peptides with potent and broad-spectrum antimicrobial activities. | Int J Antimicrob Agents | 2006